The prognostic role of platelet-to-lymphocyte ratio on overall survival in gastric cancer: a systematic review and meta-analysis

Table 3 Subgroup analysis for overall survival

Factor	Groups	Number of cohorts	HR and 95% CI	P value	Heterogeneity (%)	P value for heterogeneity	P value between subgroups
Study design	Prospective	2	1.05 (0.87–1.27)	0.625	0.0	0.868	0.022
Study design	Retrospective	28	1.40 (1.26–1.55)	< 0.001	68.6	< 0.001	0.022
Country	China	19	1.32 (1.16–1.49)	< 0.001	75.0	< 0.001	0.045
	Japan or Korea	3	1.45 (0.94–2.25)	0.092	71.4	0.030
	Other	8	1.51 (1.33–1.72)	< 0.001	0.0	0.503
Sample size	≥ 1000	11	1.25 (1.09–1.45)	0.002	69.2	< 0.001	< 0.001
Sample size	< 1000	19	1.44 (1.28–1.63)	< 0.001	60.4	< 0.001	< 0.001
Percent male	≥ 70.0	10	1.31 (1.10–1.55)	0.002	72.9	< 0.001	0.014
Percent male	< 70.0	20	1.40 (1.25–1.58)	< 0.001	63.5	< 0.001	0.014
Mean age (years)	≥ 60.0	13	1.41 (1.16–1.71)	0.001	82.2	< 0.001	0.168
Mean age (years)	< 60.0	12	1.39 (1.23–1.57)	< 0.001	41.6	0.064	0.168
Treatment strategy	Surgery	14	1.21 (1.08–1.35)	0.001	56.5	0.005	< 0.001
	Chemotherapy	6	1.70 (1.43–2.03)	< 0.001	40.4	0.136
	Mixed	10	1.44 (1.31–1.59)	< 0.001	0.0	0.545
Disease status	Early	6	1.18 (1.04–1.34)	0.012	0.0	0.533	0.076
	Advanced	13	1.51 (1.26–1.82)	< 0.001	82.0	< 0.001
	All	11	1.29 (1.14–1.45)	< 0.001	35.1	0.118
Cutoff value	≥ 200	6	1.79 (1.43–2.24)	< 0.001	56.8	0.041	< 0.001
Cutoff value	< 200	24	1.28 (1.17–1.40)	< 0.001	53.9	0.001	< 0.001
NOS scale	High	24	1.34 (1.20–1.50)	< 0.001	72.0	< 0.001	0.039
NOS scale	Low	6	1.49 (1.30–1.72)	< 0.001	0.0	0.416	0.039

ISSN: 1471-230X